Pfizer and BioNTech Elicits Strong T-cell Response in P-I/II Study Against COVID-19


  • The companies reported that most advanced of four COVID-19 vaccine candidates from their BNT162 mRNA-based vaccine program demonstrated the ability to elicit high SARS-CoV-2 neutralizing titers following the second dose in an ongoing P-I/II study in Germany
  • The results divulge that BNT162b1 candidate induced strong CD4+ and CD8+ T-cell responses. BNT162b1 elicits RBD-specific, interferon-g+, IL-2+, CD8+ T cells in immunized participants indicating a strong potential for cell-mediated anti-viral activity
  • BNT162b1 induced broad neutralizing activity in pseudovirus neutralization assays across a panel of 16 SARS-CoV-2 RBD variants, including D614G strain. Data from German and US P-I/II studies will be used by the two companies to determine a dose level and select among multiple vaccine candidates to seek to progress in global P-IIb/III safety and efficacy trial, expected to begin in Jul’20 end

Click here to read full press release/ article | Ref: Businesswire | Image: Barron

Related News: Pfizer and BioNTech Report Results of BNT162b1 mRNA-Based Vaccine in P-I/II Study Against COVID-19